Sökning: WFRF:(Chasen Beth)
> (2021) >
Symptom Diaries of ...
Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-DOTATATE
-
- Strosberg, Jonathan R. (författare)
- H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
-
- Srirajaskanthan, Rajaventhan (författare)
- Kings Coll Hosp London, Dept Gastroenterol, Neuroendocrine Tumour Unit, London, England.
-
- El-Haddad, Ghassan (författare)
- H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
-
visa fler...
-
- Wolin, Edward M. (författare)
- Tish Canc Inst Mt Sinai, Ctr Carcinoid & Neuroendocrine Tumors, New York, NY USA.
-
- Chasen, Beth R. (författare)
- Univ Texas MD Anderson Canc Ctr, Dept Nucl Med, Div Diagnost Imaging, Houston, TX 77030 USA.
-
- Kulke, Matthew H. (författare)
- Boston Univ, Sect Hematol & Med Oncol, Boston, MA 02215 USA.;Boston Med Ctr, Boston, MA 02215 USA.
-
- Bushnell, David L. (författare)
- Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA.
-
- Caplin, Martyn E. (författare)
- Royal Free Hosp, Neuroendocrine Tumour Unit, London, England.
-
- Baum, Richard P. (författare)
- DKD Helios Clin, Curanosticum Wiesbaden Frankfurt, Wiesbaden, Germany.
-
- Hendifar, Andrew E. (författare)
- Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA.
-
- Öberg, Kjell, 1946- (författare)
- Uppsala universitet,Endokrin tumörbiologi
-
- Ruszniewski, Philippe (författare)
- Div Gastroenterol & Pancreatol, Hop Beaujon, Clichy, France.
-
- Santoro, Paola (författare)
- Adv Accelerator Applicat, Millburn, NJ USA.
-
- Broberg, Per (författare)
- Adv Accelerator Applicat, Geneva, Switzerland.
-
- Leeuwenkamp, Oscar R. (författare)
- Adv Accelerator Applicat, Geneva, Switzerland.
-
- Krenning, Eric P. (författare)
- Erasmus MC, Cyclotron Rotterdam BV, Rotterdam, Netherlands.
-
visa färre...
-
H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA Kings Coll Hosp London, Dept Gastroenterol, Neuroendocrine Tumour Unit, London, England. (creator_code:org_t)
- 2021-03-26
- 2021
- Engelska.
-
Ingår i: Journal of Nuclear Medicine. - : Society of Nuclear Medicine. - 0161-5505 .- 1535-5667 .- 2159-662X. ; 62:12, s. 1712-1718
- Relaterad länk:
-
https://doi.org/10.2...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://jnm.snmjourn...
-
https://urn.kb.se/re...
-
https://doi.org/10.2...
-
visa färre...
Abstract
Ämnesord
Stäng
- We report the impact of 177Lu-DOTATATE treatment on abdominal pain, diarrhea, and flushing, symptoms that patients with advanced midgut neuroendocrine tumors often find burdensome.Methods: All patients enrolled in the international randomized phase 3 Neuroendocrine Tumors Therapy (NETTER-1) trial (177Lu-DOTATATE plus standard-dose octreotide long-acting repeatable [LAR], n = 117; high-dose octreotide LAR, n = 114) were asked to record the occurrence of predefined symptoms in a daily diary. Change from baseline in symptom scores (mean number of days with a symptom) was analyzed using a mixed model for repeated measures.Results: Patients (intent-to-treat) who received 177Lu-DOTATATE experienced a significantly greater decline from baseline in symptom scores than patients who received high-dose octreotide LAR. For 177Lu-DOTATATE, the mean decline in days with abdominal pain, diarrhea, and flushing was 4.10, 4.55, and 4.52 d per 4 wk, respectively, compared with 0.99, 1.44, and 2.54 d for high-dose octreotide LAR. The mean differences were 3.11 d (95% CI, 1.35–4.88; P = 0.0007) for abdominal pain, 3.11 d (1.18–5.04; P = 0.0017) for diarrhea, and 1.98 d (0.08–3.88; P = 0.0413) for flushing, favoring 177Lu-DOTATATE. A positive repeated-measures correlation was found between diary-recorded symptom scores and questionnaire-recorded pain, diarrhea, and flushing.Conclusion: In addition to efficacy and quality-of-life benefits, symptom diaries from NETTER-1 demonstrated that treatment with 177Lu-DOTATATE was associated with statistically significant reductions in abdominal pain, diarrhea, and flushing, constituting the core symptoms of patients with progressive midgut neuroendocrine tumors, compared with high-dose octreotide LAR, supporting a beneficial effect of 177Lu-DOTATATE on health-related quality of life.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Radiologi och bildbehandling (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Radiology, Nuclear Medicine and Medical Imaging (hsv//eng)
Nyckelord
- 177Lu
- neuroendocrine
- symptom diary
- NETTER-1
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Strosberg, Jonat ...
-
Srirajaskanthan, ...
-
El-Haddad, Ghass ...
-
Wolin, Edward M.
-
Chasen, Beth R.
-
Kulke, Matthew H ...
-
visa fler...
-
Bushnell, David ...
-
Caplin, Martyn E ...
-
Baum, Richard P.
-
Hendifar, Andrew ...
-
Öberg, Kjell, 19 ...
-
Ruszniewski, Phi ...
-
Santoro, Paola
-
Broberg, Per
-
Leeuwenkamp, Osc ...
-
Krenning, Eric P ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Radiologi och bi ...
- Artiklar i publikationen
-
Journal of Nucle ...
- Av lärosätet
-
Uppsala universitet